Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Carcinoma, Hepatocellular 18Stomach Neoplasms 17Nasopharyngeal Carcinoma 15Triple Negative Breast Neoplasms 13Esophageal Squamous Cell Carcinoma 13Breast Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Esophageal Neoplasms 11Uterine Cervical Neoplasms 10Colorectal Neoplasms 10Sarcoma 9Melanoma 6Recurrence 5Neoplasm Metastasis 5Lung Neoplasms 5Hodgkin Disease 5Cholangiocarcinoma 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Osteosarcoma 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Liver Neoplasms 3Glioblastoma 3Gestational Trophoblastic Disease 3Endometrial Neoplasms 3Biliary Tract Neoplasms 3Solid Tumor 2Rectal Neoplasms 2NSCLC 2

Interventions

Gemcitabine 2durvalumab 1camrelizumab 1apatinib 1Tegafur 1Surgical Procedures, Operative 1Oxaliplatin 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Biliary Tract Carcinoma × camrelizumab × Clear all
NCT05451290 2026-02-12

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

First Affiliated Hospital of Zhejiang University

Phase 2 Active not recruiting
30 enrolled
Gastrointestinal

Advanced Biliary Tract Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡